These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 16930141

  • 1. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
    Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G, Console G, Iacopino P.
    Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
    [Abstract] [Full Text] [Related]

  • 2. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.
    Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P.
    Bone Marrow Transplant; 2005 May; 35(9):889-93. PubMed ID: 15765110
    [Abstract] [Full Text] [Related]

  • 3. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
    Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R, Kobbe G.
    Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
    [Abstract] [Full Text] [Related]

  • 4. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
    Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG.
    Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
    Kroschinsky F, Hölig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, Oelschlaegel U, Schaich M, Hänel M, Bornhäuser M, Ehninger G.
    Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
    [Abstract] [Full Text] [Related]

  • 6. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.
    Samaras P, Blickenstorfer M, Siciliano RD, Haile SR, Buset EM, Petrausch U, Mischo A, Honegger H, Schanz U, Stussi G, Stahel RA, Knuth A, Stenner-Liewen F, Renner C.
    Ann Hematol; 2011 Jan; 90(1):89-94. PubMed ID: 20706722
    [Abstract] [Full Text] [Related]

  • 7. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
    Vanstraelen G, Frère P, Ngirabacu MC, Willems E, Fillet G, Beguin Y.
    Exp Hematol; 2006 Mar; 34(3):382-8. PubMed ID: 16543072
    [Abstract] [Full Text] [Related]

  • 8. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
    Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R.
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):186-91. PubMed ID: 20511163
    [Abstract] [Full Text] [Related]

  • 9. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N.
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [Abstract] [Full Text] [Related]

  • 10. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
    Sebban C, Lefranc A, Perrier L, Moreau P, Espinouse D, Schmidt A, Kammoun L, Ghesquieres H, Ferlay C, Bay JO, Lissandre S, Pérol D, Michallet M, Quittet P.
    Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
    [Abstract] [Full Text] [Related]

  • 11. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas.
    Ballestrero A, Boy D, Gonella R, Miglino M, Clavio M, Barbero V, Nencioni A, Gobbi M, Patrone F.
    Ann Hematol; 2008 Jan; 87(1):49-55. PubMed ID: 17710398
    [Abstract] [Full Text] [Related]

  • 12. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
    Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, Hübel K, Haas R, Kobbe G.
    Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
    [Abstract] [Full Text] [Related]

  • 13. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.
    Clin Ther; 2009 Feb; 31 Pt 2():2388-95. PubMed ID: 20110048
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C.
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [Abstract] [Full Text] [Related]

  • 15. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
    Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Gräf T, Rohr UP, Bork S, Kronenwett R, Haas R, Kobbe G.
    Bone Marrow Transplant; 2005 Jan; 35(1):33-6. PubMed ID: 15531906
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens.
    Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Baraté C, Scarpati B, Santoleri L, Nador G, Pezzetti L, Morra E.
    Bone Marrow Transplant; 2006 Sep; 38(6):413-6. PubMed ID: 16878144
    [Abstract] [Full Text] [Related]

  • 17. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.
    Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Körbling M, Champlin RE.
    Br J Haematol; 2006 Jun; 133(5):533-7. PubMed ID: 16681642
    [Abstract] [Full Text] [Related]

  • 18. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.
    Gerds A, Fox-Geiman M, Dawravoo K, Rodriguez T, Toor A, Smith S, Kiley K, Fletcher-Gonzalez D, Hicks C, Stiff P.
    Biol Blood Marrow Transplant; 2010 May; 16(5):678-85. PubMed ID: 20045479
    [Abstract] [Full Text] [Related]

  • 19. Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
    Samaras P, Buset EM, Siciliano RD, Haile SR, Petrausch U, Mischo A, Honegger H, Pestalozzi BC, Schanz U, Stussi G, Stahel RA, Knuth A, Renner C, Stenner-Liewen F.
    Oncology; 2010 May; 79(1-2):93-7. PubMed ID: 21079406
    [Abstract] [Full Text] [Related]

  • 20. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
    Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M.
    Haematologica; 2008 Nov; 93(11):1739-42. PubMed ID: 18728024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.